Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications
Y Kawabata, K Wada, M Nakatani, S Yamada… - International journal of …, 2011 - Elsevier
The poor oral bioavailability arising from poor aqueous solubility should make drug research
and development more difficult. Various approaches have been developed with a focus on …
and development more difficult. Various approaches have been developed with a focus on …
Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs
Solid dispersions are one of the most promising strategies to improve the oral bioavailability
of poorly water soluble drugs. By reducing drug particle size to the absolute minimum, and …
of poorly water soluble drugs. By reducing drug particle size to the absolute minimum, and …
Strategies for improving bioavailability, bioactivity, and physical-chemical behavior of curcumin
Curcumin (CCM) is one of the most frequently explored plant compounds with various
biological actions such as antibacterial, antiviral, antifungal, antineoplastic, and …
biological actions such as antibacterial, antiviral, antifungal, antineoplastic, and …
Physical chemistry of solid dispersions
S Janssens, G Van den Mooter - Journal of Pharmacy and …, 2009 - academic.oup.com
Objectives With poorly soluble drug candidates emerging in the drug discovery pipeline, the
importance of the solid dispersion formulation approach is increasing. This strategy includes …
importance of the solid dispersion formulation approach is increasing. This strategy includes …
Are pharmaceuticals potent environmental pollutants?: Part I: Environmental risk assessments of selected active pharmaceutical ingredients
C Carlsson, AK Johansson, G Alvan, K Bergman… - Science of the total …, 2006 - Elsevier
As part of achieving national environmental goals, the Swedish Government commissioned
an official report from the Swedish Medical Products Agency on environmental effects of …
an official report from the Swedish Medical Products Agency on environmental effects of …
Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration
BM Davit, PE Nwakama, GJ Buehler… - Annals of …, 2009 - journals.sagepub.com
Background: In the US, manufacturers seeking approval to market a generic drug product
must submit data demonstrating that the generic formulation provides the same rate and …
must submit data demonstrating that the generic formulation provides the same rate and …
Application of surfactants in solid dispersion technology for improving solubility of poorly water soluble drugs
SP Chaudhari, RP Dugar - Journal of drug delivery science and technology, 2017 - Elsevier
Discovery of several poorly water soluble drugs in the past decade has led to the constant
need of developing a novel dosage form which increases the solubility of these drug. They …
need of developing a novel dosage form which increases the solubility of these drug. They …
Solid dispersion as an approach for bioavailability enhancement of poorly water-soluble drug ritonavir
Ritonavir is an antiretroviral drug characterized by low solubility and high permeability which
corresponds to BCS class II drug. The purpose of the study was to develop solid dispersion …
corresponds to BCS class II drug. The purpose of the study was to develop solid dispersion …
Optimizing oral bioavailability in drug discovery: an overview of design and testing strategies and formulation options
BJ Aungst - Journal of pharmaceutical sciences, 2017 - Elsevier
For discovery teams working toward new, orally administered therapeutic agents, one
requirement is to attain adequate systemic exposure after oral dosing, which is best …
requirement is to attain adequate systemic exposure after oral dosing, which is best …
Soft gelatin capsules (softgels)
RP Gullapalli - Journal of pharmaceutical sciences, 2010 - Elsevier
It is estimated that more than 40% of new chemical entities (NCEs) coming out of the current
drug discovery process have poor biopharmaceutical properties, such as low aqueous …
drug discovery process have poor biopharmaceutical properties, such as low aqueous …